This is a US news story, published by The Limbic.
For more US news, you can click here:
more US newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from The Limbic, you can click here:
more news from The LimbicOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
oncology trials. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest clinical trials news, most trials news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
early phase oncology trialsThe Limbic
•81% Informative
There were 493 phase 1 clinical trials registered for systemic therapies in solid cancers across 71 Australian sites between 2012 and 2022 .
The number of trials registered per year increased from 18 in 2012 to 75 in 2022 , with immunomodulatory ( 45% ) and targeted approaches ( 44% ) accounting for most drug classes.
In 2012 , most phase 1 trials ( 78% ) were sponsored by large pharmaceutical companies, but by 2022 most trials ( 67% ) were sponsored by emerging biopharmaceutical companies.
US -based companies sponsored most trials over the ten year period ( 42% ).
VR Score
92
Informative language
98
Neutral language
77
Article tone
formal
Language
English
Language complexity
51
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links